Author

N. T. Jui

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Organism:human· 2 Approach:deep learning· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

D. DeRyckere· 2 shared D. K. Graham· 2 shared D. Melchers· 2 shared E. A. Ortlund· 2 shared E. C. Dreaden· 2 shared E. H. D'Agostino· 2 shared H. Fu· 2 shared H. Zecca· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

D. DeRyckere

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

J. M. Kelvin, J. Jain, A. Thapa, M. Qui, L. A. Birnbaum, S. G. Moore, H. Zecca, R. J. Summers, E. Costanza, B. Uricoli, X. Wang, N. T. Jui, H. Fu, Y. Du, D. DeRyckere, , E. C. Dreaden

The paper develops a nanoscale combination drug formulation targeting MERTK, FLT3, and BCL-2 to treat AML, showing improved synergistic responses in vitro and in patient samples.

bioRxiv · Mar 13, 2023 · PreprintBioengineering

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia

J. M. Kelvin, D. Y. Zhang, E. K. Williams, S. G. Moore, L. A. Birnbaum, H. Zecca, X. Wang, J. Jain, M. Qui, N. T. Jui, H. Fu, Y. Du, M. L. Kemp, W. A. Lam, D. DeRyckere, , E. C. Dreaden

The paper identifies synergistic drug combinations for T-ALL using high-throughput screens and develops lipid nanoparticle formulations that maintain drug synergy and improve anti-leukemic activity.

bioRxiv · Sep 21, 2022 · PreprintBioengineering

Tapping into a phospholipid-LRH-1 axis yields a powerful anti-inflammatory agent with in vivo activity against colitis

S. G. Mays, E. H. D'Agostino, A. R. Flynn, X. Huang, G. Wang, X. Liu, E. J. Millings, C. D. Okafor, A. Patel, M. L. Cato, J. L. Cornelison, D. Melchers, R. Houtman, D. D. Moore, J. W. Calvert, , E. A. Ortlund

The paper develops a phospholipid-mimicking LRH-1 agonist that shows in vivo efficacy in a colitis model by improving binding affinity and transcriptional activity.

bioRxiv · Sep 1, 2020 · PreprintBiochemistry

Development of a new class of liver receptor homolog-1 (LRH-1) agonists by photoredox conjugate addition

J. L. Cornelison, M. L. Cato, A. M. Johnson, E. H. D'Agostino, D. Melchers, A. B. Patel, S. G. Mays, R. Houtman, E. A. Ortlund, N. T. Jui

This study develops a new class of LRH-1 agonists using a photoredox conjugate addition method, enabling bridgehead substitution to enhance ligand activation.

bioRxiv · Mar 16, 2020Biochemistry